並列タイトル等持続的腎代替療法におけるメシル酸ナファモスタットの血中動態
一般注記type:Thesis
Continuous renal replacement therapy (CRRT) is the preferred dialysis modalityin critical care settings for patients with hemodynamic instability. Nafamostatmesylate (NM) is an anticoagulant commonly used (mainly in Japan)during CRRT in patients with high bleeding risk. In this study, we evaluatedthe pharmacokinetics of NM during CRRT. Patients undergoing CRRTtherapy and using NM as the anticoagulant in the intensive care unit wereenrolled in the study. Blood was collected from the CRRT circuit just afterblood removal, just before and after the membrane for CRRT, and from thefiltrates after the membrane. NM concentrations were measured usinghigh-performance liquid chromatography. NM was detected in the intracorporealcirculation during CRRT in some cases, and liver enzymes were severelyelevated in almost all of the cases. Coagulation time was prolongedeven before the initiation of NM administration in these cases and may beassociated with liver damage. This study suggests that NM dosage should takeinto account liver damage assessed by elevated liver enzymes.
博士（医学）・乙第1531号・令和5年3月15日
© 2022 by author(s) and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).
identifier:Emergency Medicine Vol.10 No.4 p.157-167 (2022 Dec)
identifier:23321806
identifier:http://ginmu.naramed-u.ac.jp/dspace/handle/10564/4116
identifier:Emergency Medicine, 10(4): 157-167
コレクション（個別）国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文
受理日（W3CDTF）2023-12-05T21:41:08+09:00
連携機関・データベース国立国会図書館 : 国立国会図書館デジタルコレクション